TY - JOUR T1 - Measuring cystic fibrosis drug responses in organoids derived from 2D differentiated nasal epithelia JF - Life Science Alliance JO - Life Sci. Alliance DO - 10.26508/lsa.202101320 VL - 5 IS - 12 SP - e202101320 AU - Gimano D Amatngalim AU - Lisa W Rodenburg AU - Bente L Aalbers AU - Henriette HM Raeven AU - Ellen M Aarts AU - Dounia Sarhane AU - Sacha Spelier AU - Juliet W Lefferts AU - Iris AL Silva AU - Wilco Nijenhuis AU - Sacha Vrendenbarg AU - Evelien Kruisselbrink AU - Jesse E Brunsveld AU - Cornelis M van Drunen AU - Sabine Michel AU - Karin M de Winter-de Groot AU - Harry G Heijerman AU - Lukas C Kapitein AU - Magarida D Amaral AU - Cornelis K van der Ent AU - Jeffrey M Beekman Y1 - 2022/12/01 UR - https://www.life-science-alliance.org/content/5/12/e202101320.abstract N2 - Cystic fibrosis is caused by genetic defects that impair the CFTR channel in airway epithelial cells. These defects may be overcome by specific CFTR modulating drugs, for which the efficacy can be predicted in a personalized manner using 3D nasal-brushing–derived airway organoids in a forskolin-induced swelling assay. Despite of this, previously described CFTR function assays in 3D airway organoids were not fully optimal, because of inefficient organoid differentiation and limited scalability. In this report, we therefore describe an alternative method of culturing nasal-brushing–derived airway organoids, which are created from an equally differentiated airway epithelial monolayer of a 2D air–liquid interface culture. In addition, we have defined organoid culture conditions, with the growth factor/cytokine combination neuregulin-1β and interleukin-1β, which enabled consistent detection of CFTR modulator responses in nasal-airway organoid cultures from subjects with cystic fibrosis. ER -